ABSTRACT
Veterinary Hemaseel consists of two components: a coagulation protein component containing mostly fibrinogen and a thrombin component. The coagulation protein component is obtained from freshly collected bovine blood, which is separated in the laboratory into plasma and blood-cell fractions. Following this, plasma is frozen at a temperature below -30°C in transfer bags for a minimum of twenty-four hours. The plasma is then processed as described in a separate communication from this laboratory in order to obtain solvent/detergent (S/D) virusinactivated, coagulation protein component [1]. The thrombin component, being also subjected to S/D treatment, is obtained from a crude, commercial thrombin preparation. According to current data, this is the first S/D-treated fibrin sealant derived from bovine plasma. Fibrin formation is responsible for the haemostatic properties of the coagulation protein component and is instrumental in the adherence to adjacent tissues. Therefore, the experience and knowledge gained from the in vivo and ex vivo studies of this bovine product are of great value.
